Positive FDG-PET/CT Scans of a Residual Seminoma After Chemotherapy and Radiotherapy: Case Report and Review of the Literature

Overview

Journal Clin Genitourin Cancer

Publisher Elsevier

Specialties Oncology
Urology

Date 2014 Mar 29

PMID 24674785

Citations 3

Authors

Mehmet Asim Bilen

Houssam Hariri

Chady Leon

Charles C Guo

Deborah A Kuban

Louis L Pisters

Shi-Ming Tu

Affiliations

Soon will be listed here.

Citing Articles

End-of-Treatment FDG PET-CT (EOT-PET) in Patients with Post-Chemotherapy Masses for Seminoma: Can We Avoid Further Intervention?.

Joel A, Singh A, Hepzibah J, Devasia A, Kumar S, Gnanamuthu B South Asian J Cancer. 2023; 11(4):315-321.

PMID: 36756102 PMC: 9902077. DOI: 10.1055/s-0041-1735480.

Imaging of the scrotum: beyond sonography.

Parenti G, Feletti F, Carnevale A, Uccelli L, Giganti M Insights Imaging. 2018; 9(2):137-148.

PMID: 29450854 PMC: 5893488. DOI: 10.1007/s13244-017-0592-z.

Intraoperative Molecular Imaging for Post-Chemotherapy Robot-Assisted Laparoscopic Resection of Seminoma Metastasis: A Case Report.

Xia L, Venegas O, Predina J, Singhal S, Guzzo T Clin Genitourin Cancer. 2016; 15(1):e61-e64.

PMID: 27793611 PMC: 10998540. DOI: 10.1016/j.clgc.2016.09.007.

References

Herr H, Sheinfeld J, Puc H, Heelan R, Bajorin D, Mencel P . Surgery for a post-chemotherapy residual mass in seminoma. J Urol. 1997; 157(3):860-2. View

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F . European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008; 53(3):497-513. DOI: 10.1016/j.eururo.2007.12.025. View

Choo R, Quevedo F, Choo C, Blute M . Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma?. Can Urol Assoc J. 2010; 4(5):E137-40. PMC: 2950770. DOI: 10.5489/cuaj.937. View

De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F . 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004; 22(6):1034-9. DOI: 10.1200/JCO.2004.07.188. View

Puc H, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V . Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1996; 14(2):454-60. DOI: 10.1200/JCO.1996.14.2.454. View

Becherer A, De Santis M, Karanikas G, Szabo M, Bokemeyer C, Dohmen B . FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol. 2005; 54(2):284-8. DOI: 10.1016/j.ejrad.2004.07.012. View

Hinz S, Schrader M, Kempkensteffen C, Bares R, Brenner W, Krege S . The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol. 2008; 179(3):936-40. DOI: 10.1016/j.juro.2007.10.054. View

Mosharafa A, Foster R, Leibovich B, Bihrle R, Johnson C, Donohue J . Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?. J Urol. 2003; 169(6):2126-8. DOI: 10.1097/01.ju.0000060121.33899.4b. View

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F . European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008; 53(3):478-96. DOI: 10.1016/j.eururo.2007.12.024. View

10.

De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K . Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol. 2001; 19(17):3740-4. DOI: 10.1200/JCO.2001.19.17.3740. View

11.

Muller J, Schrader A, Jentzmik F, Schrader M . [Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value]. Urologe A. 2010; 50(3):322-7. DOI: 10.1007/s00120-010-2469-3. View

12.

Duchesne G, Stenning S, Aass N, Mead G, Fossa S, Oliver R . Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer. 1997; 33(6):829-35. DOI: 10.1016/s0959-8049(97)00033-6. View

13.

Schultz S, Einhorn L, Conces Jr D, Williams S, Loehrer P . Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol. 1989; 7(10):1497-503. DOI: 10.1200/JCO.1989.7.10.1497. View

14.

Som A, Zhu R, Guo C, Efstathiou E, Xiao L, Pisters L . Recurrent seminomas: clinical features and biologic implications. Urol Oncol. 2010; 30(4):494-501. PMC: 3856193. DOI: 10.1016/j.urolonc.2010.05.011. View

15.

Flechon A, Bompas E, Biron P, Droz J . Management of post-chemotherapy residual masses in advanced seminoma. J Urol. 2002; 168(5):1975-9. DOI: 10.1016/S0022-5347(05)64275-9. View

16.

Ganjoo K, Chan R, Sharma M, Einhorn L . Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol. 1999; 17(11):3457-60. DOI: 10.1200/JCO.1999.17.11.3457. View

17.

Peckham M, Horwich A, HENDRY W . Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br J Cancer. 1985; 52(1):7-13. PMC: 1977156. DOI: 10.1038/bjc.1985.141. View

18.

Motzer R, Agarwal N, Beard C, Bolger G, Boston B, Carducci M . NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 2009; 7(6):672-93. DOI: 10.6004/jnccn.2009.0047. View